Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis

Nicola De Stefano1, Maria Letizia Bartolozzi, Benedetta Nacmias

  • 1Department of Neurological and Behavioral Sciences, University of Siena, Siena, Italy. destefano@unisi.it

Archives of Neurology
|April 21, 2004
PubMed
Abstract

Insights

The apolipoprotein E (ApoE) epsilon4 allele is linked to reduced brain volume in relapsing-remitting multiple sclerosis (RRMS) patients, indicating impaired repair mechanisms even in early disease stages.

Area of Science:

  • Neuroscience
  • Genetics
  • Neurology

Background:

  • Multiple sclerosis (MS) patients with the apolipoprotein E (ApoE) epsilon4 allele may experience a more severe disease course.
  • This is potentially due to increased tissue destruction and reduced neuronal repair in ApoE epsilon4 carriers.

Purpose of the Study:

  • To investigate the impact of different ApoE genotypes on brain tissue integrity in relapsing-remitting MS (RRMS) patients.

Main Methods:

  • ApoE genotyping was performed on 76 RRMS patients.
  • Conventional MRI (T1, T2, proton density) was used to assess brain volumes and lesion load.
  • Automated analysis quantified normalized brain volumes (NBVs).

Main Results:

  • ApoE epsilon4 carriers showed significantly lower NBVs compared to controls and non-epsilon4 carriers (P=.01).
  • This reduction in NBV was observed even in RRMS patients with early disease and no clinical disability (P=.02 vs. non-carriers, P=.007 vs. controls).
  • No significant differences in total brain lesion volume were found across ApoE genotypes.

Conclusions:

  • The ApoE epsilon4 genotype is associated with decreased normalized brain volumes in RRMS patients.
  • This suggests impaired cell repair mechanisms and severe tissue destruction linked to ApoE epsilon4.
  • The negative effects of the ApoE epsilon4 genotype appear to be present from the early stages of MS.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...